Figure 2 Clinical parameters in patients with psoriatic arthritis (PsA) who switched from infliximab to etanercept (n = 10, column 1) and from etanercept to adalimumab (n = 7, column 2). Box and whiskers plot (median, quartiles, range and possible extreme values) of (A) tender joint count, (B) swollen joint count, (C) patient and (D) physician global assessment (on visual analogue scale), and (E) percentage of patients who met Psoriatic Arthritis Response Criteria (PsARC). Values shown in column 1 are the mean values at baseline (before infliximab treatment), after 3 months of infliximab treatment, at last visit while on infliximab, at baseline (before etanercept treatment) and after 3 months of etanercept treatment. Values shown in column 2 are the mean values at baseline (before etanercept treatment), after 3 months of etanercept treatment, at last visit while on etanercept, at baseline (before adalimumab treatment) and after 3 months of adalimumab treatment.